Kelly Davio

Amgen’s ABP 501 (Amjevita) shows similar efficacy to the reference adalimumab (Humira) in treating rheumatoid arthritis and supported approval of the biosimilar by the FDA.

Lawsuit alleges that patients paid artificially high prices for brand-name Humira, and that they were deprived of the benefits of early, robust competition from biosimilars as a result of wrongful conduct.

Fenfluramine, a drug that was previously sold as an appetite suppressant before it was withdrawn from the market in 1997 over concerns about its link to heart valve problems, may have a new application.

Fenfluramine, a drug that was previously sold as an appetite suppressant before it was withdrawn from the market in 1997 over concerns about its link to heart valve problems, may have a new application.

The FDA on Friday approved Pfizer's filgrastim-aafi, a filgrastim biosimilar to Amgen's Neupogen.

Elotuzumab with pomalidomide and low-dose dexamethasone met its primary endpoint in showing a statistically significant, clinically meaningful improvement in progression-free survival in patients with relapsed/refractory multiple myeloma.

Officials with the FDA have granted GBC0905, for the treatment of facioscapulohumeral muscular dystrophy (FSHD), an Orphan Drug Designation.

Lonafarnib, a farnesyltransferase inhibitor, extended survival in patients with Hutchinson-Gilford progeria syndrome, or progeria.

Some studies have suggested that patients with HIV have not only a higher risk of lung cancer, but also an increased risk of mortality from lung cancer than patients without HIV.

New data may support the potential of achieving clinical benefits by using CAR T cells in patients with glioblastoma.

In an effort to evaluate whether switching from a reference biologic to a biosimilar could lead to altered clinical outcome, a research team, led by Hillel Cohen, PhD, conducted a systematic literature review of all available switching studies.